Capital loss incited Zuellig to aggressive business strategies.

According to a financial report disclosed by a Zuellig's associated drug company, Zuellig Korea (President: Christian Stockling) made slow business progress last year to an extent that they encountered a whole capital lose and their associated drug makers who invested in business deals for sales, credit collections and a third party experienced fatal investment damages.

Mr. Stockling sai...